December 11, 2024 Update

We've published a detailed analysis of Test Report #53346, which provides a comprehensive guide to reading and verifying peptide test reports. This case study shows exceptional purity levels (99.803%) and proper pharmaceutical overfill (+7.4%), demonstrating the importance of independent verification. For a complete walkthrough of how to read and verify test reports, see our Understanding Peptide Test Reports guide.

In the evolving landscape of GLP-1 medications, laboratory testing data has become a crucial tool for understanding product quality. Analysis of over 85 independent tests conducted between September and November 2024 provides unprecedented insights into quality control standards and consistency.

While analyzing test results, use our GLP-1 Plotter to track and visualize your prescribed medication levels over time.

85+
Independent Lab Tests
12+
Vendors Analyzed
4
Testing Facilities
25+
Active Testing Groups

Data Sources and Methodology

Testing Data Sources (December 2024)

  • 25+ active testing groups
  • 85+ verified lab results
  • 3 primary testing labs: Peptide Test, Janoshik, Vanguard
  • Data period: Sept-Dec 2024

Current Testing Initiatives

Active Testing Groups

  • AMO T30/L30 November batches (multiple groups)
  • ASC T10-T30 verification testing
  • SRY T30/T60 batch analysis
  • QSC Black November quality control

Quality Analysis Results

Microdose Tools & Resources

🧪
Microdose Calculator
Split-dose math
 📅
Microdose Schedule
Daily/EOD cadences
 📈
Plasma Plotter
Compare microdose vs weekly
 🔗
Standard-Dose View
GLP1Calculator article
Disclaimer: GLP1Microdose.com is independent and not affiliated with Novo Nordisk, Eli Lilly, or any pharmaceutical manufacturer. Microdosing protocols are not FDA-approved dosing regimens. This article is educational only and does not constitute medical advice.